1040 related articles for article (PubMed ID: 28300812)
1. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
2. [Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach].
Krupitsky ЕМ; Kibitov АО; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Kosten Т; Nielsen D; Zvartau EE; Woody D
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(4 Pt 2):14-23. PubMed ID: 26288297
[TBL] [Abstract][Full Text] [Related]
3. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
4. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
5. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
6. Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration.
Lechner WV; Knopik VS; McGeary JE; Spillane NS; Tidey JW; McKee SA; Metrik J; Leventhal AM; Rohsenow DJ; Kahler CW
Nicotine Tob Res; 2016 May; 18(5):632-6. PubMed ID: 26092968
[TBL] [Abstract][Full Text] [Related]
7. Association between dopaminergic polymorphisms and borderline personality traits among at-risk young adults and psychiatric inpatients.
Nemoda Z; Lyons-Ruth K; Szekely A; Bertha E; Faludi G; Sasvari-Szekely M
Behav Brain Funct; 2010 Jan; 6():4. PubMed ID: 20205808
[TBL] [Abstract][Full Text] [Related]
8. [Combination of DAT and DBH gene polymorphisms with a family history of alcohol use disorders increases the risk of withdrawal seizures and delirium tremens during alcohol withdrawal in alcohol-dependent men].
Kibitov AO; Ivashchenko DV; Brodyansky VM; Chuprova NA; Shuvalov SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):68-80. PubMed ID: 28139629
[TBL] [Abstract][Full Text] [Related]
9. Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies.
Chen D; Liu F; Shang Q; Song X; Miao X; Wang Z
Am J Med Genet B Neuropsychiatr Genet; 2011 Sep; 156B(6):661-70. PubMed ID: 21714067
[TBL] [Abstract][Full Text] [Related]
10. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
11. Association study of DRD2 A2/A1, DRD3 Ser9Gly, DβH -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence.
Ragia G; Veresies I; Veresie L; Veresies K; Manolopoulos VG
Drug Metab Pers Ther; 2016 Sep; 31(3):143-50. PubMed ID: 27447243
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the cellular composition and of the inflammatory response activity in the lymph nodes of patients with sarcoidosis at different stages of the clinical course and treatment with systemic glucocorticosteroids].
Ніколєнко ДЄ; Бойко ДМ
Wiad Lek; 2017; 70(1):32-37. PubMed ID: 28343190
[TBL] [Abstract][Full Text] [Related]
15. Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder.
Hirasawa-Fujita M; Bly MJ; Ellingrod VL; Dalack GW; Domino EF
Clin Schizophr Relat Psychoses; 2017; 11(1):39-48. PubMed ID: 28548579
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese.
Gao X; Wang Y; Lang M; Yuan L; Reece AS; Wang W
OMICS; 2017 Jul; 21(7):404-412. PubMed ID: 28692418
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
[TBL] [Abstract][Full Text] [Related]
18. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
[TBL] [Abstract][Full Text] [Related]
19. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
[TBL] [Abstract][Full Text] [Related]
20. ТР53 Codon 72 Polymorphism and Human Papilloma Virus-Associated Cervical Cancer in Kyrgyz Women.
Isakova J; Vinnikov D; Bukuev N; Talaibekova E; Aldasheva N
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1057-1062. PubMed ID: 31030474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
